Corcept Therapeutic Soars, Abbott Labs Sinks, Arista Networks Jumps on AI Spending

Stock Movers

On this episode of Stock Movers:
- Corcept Therapeutic (CORT) shares soar after the pharmaceutical firm said its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in death risk compared to nab-paclitaxel alone.
- Abbott Labs (ABT) shares sink after the medical devices firm forecasted first-quarter earnings that fell short of estimates. The company also reported organic sales for the fourth quarter that missed Wall Street’s estimates.
- Arista Networks (ANET) shares jump. The company has been a beneficiary of AI-related spending, rising more than 370% since the end of 2022. Piper Sandler upgraded the stock earlier this month.

See omnystudio.com/listener for privacy information.

More description

On this episode of Stock Movers:
- Corcept Therapeutic (CORT) shares soar after the pharmaceutical firm said its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in death risk compared to nab-paclitaxel alone.
- Abbott Labs (ABT) shares sink after the medical devices firm forecasted first-quarter earnings that fell short of estimates. The company also reported organic sales for the fourth quarter that missed Wall Street’s estimates.
- Arista Networks (ANET) shares jump. The company has been a beneficiary of AI-related spending, rising more than 370% since the end of 2022. Piper Sandler upgraded the stock earlier this month.

See omnystudio.com/listener for privacy information.

2026-01-22 3 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.